Allspring Global Investments’s NovoCure NVCR Stock Holding History

Allspring Global Investments’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-521	Closed	-$8.14K	–	2197
2024 Q3	$8.14K	Sell	521 -72	-12%	-$1.31K	﹤0.01%	2117
2024 Q2	$10.2K	Buy	+593	New	+$10.4K	﹤0.01%	2191
2023 Q4	–	Sell	-146	Closed	-$2.36K	–	2571
2023 Q3	$2.36K	Buy	+146	New	+$4.21K	﹤0.01%	2707
2023 Q2	–	Sell	-24	Closed	-$1.44K	–	2790
2023 Q1	$1.44K	Hold	24	–	–	﹤0.01%	2727
2022 Q4	$1.76K	Hold	24	–	–	﹤0.01%	2852
2022 Q3	$1K	Hold	24	–	–	﹤0.01%	2851
2022 Q2	$1K	Buy	+24	New	+$1.81K	﹤0.01%	2666

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments's NVCR Position: Q4 2024 in Review

Allspring Global Investments sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 521 shares — an estimated $8.14K sold.

Allspring Global Investments first reported a position in NVCR in Q2 2022 and held it in 7 quarters. The position peaked at $10.2K in Q2 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

Allspring Global Investments reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
Allspring Global Investments sold 521 NovoCure shares in Q4 2024, an estimated $8.14K.
Allspring Global Investments first reported a position in NovoCure in Q2 2022 and held it in 7 quarters.
Allspring Global Investments's NovoCure position peaked at $10.2K in Q2 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.